Explore the Agenda
8:00 am Morning Coffee and Check-in
8:55 am Chair’s Opening Remarks
Exploring Bispecific Cell Engagers & How Refining Antibody Affinity Can Help Predict Therapeutic Outcomes & Improve Specificity
9:00 am Creating Conditionally Acting, Multifunctional Cell Engagers with Enhanced Target Selectivity & Reduced Toxicity Potential
- Tuning antibody arms: optimizing for affinity and epitope recognition to instill cooperative, selective target binding
- Integrating tuned effector modules to deliver target-selective, conditional cytokine receptor signalling
- Combining and tuning antibody arms and effector payloads in the design and engineering of novel T cell engagers
9:30 am A Landscape Analysis of Bi-/Multi-Specific Therapies
- Overview of the preclinical, clinical, and commercial landscape of Bi/Multi-Specific Therapies
- Investigating the key trends in the bispecific space – including regulatory approvals and standout formats
- Exploring what the future looks like for the bispecific field
10:00 am Invenra’s Bispecific B-Body® Platform and Trispecific T-Body™ Platform: Versatile Multispecific Systems for Broad-Spectrum ADC Discovery
- Invenra’s proprietary B-Body and T-Body multispecific platforms were built for rapid, in-format discovery as well as for simple manufacturing.Â
- We combine two multispecific platforms to provide a rapid screening system to empirically identify optimal bispecific and trispecific ADC target combinations.
- We describe the generation of a 12×12 matrix of bispecific B-Body antibodies targeting 6 antigens to identify optimal pairs for trispecific T-Body ADCs for breast cancer.
- Our approach highlights two powerful platforms for next-generation ADCs, offering promise for more effective and versatile breast cancer therapies.
10:30 am Morning Break & Speed Networking
The perfect opportunity to kickstart new connections in this speed networking session designed to help you meet a high volume of fellow bispecific experts, exchange insights, and set the stage for deeper conversations throughout the summit.
Exploring the Next Generation of Bispecific Antibodies to Enhance Efficacy & Safety for Autoimmune Indications
11:30 am Accelerating the Discovery of a Bispecific Antagonist Using AI/ML and High-Throughput Screening
- Learn how Alloy’s modular, fully human Common Light Chain (ATX-CLC) platform accelerates bispecific antibody discovery
- Hear how we rapidly identified leads with high-yield expression, optimal pairing, and streamlined functional validation.
- See how this approach enabled the creation of a potent dual antagonist bispecific targeting two distinct pathways.
12:00 pm Exploring a Novel Mechanism of Action With the Development of TCR-PD1 Agonist Bispecifics For The Treatment of Autoimmune Diseases
- Aiming to deliver tissue-specific TCR-based therapeutics
- Adapting the ImmTAC platform with a novel effector function to address autoimmune diseases
- Exploring the Development of a beta-cell targeted Immune Suppressive PD-1 Agonist Bispecific to treat type I diabetes
12:30 pm From ADCs to Bispecific: Supporting Innovators in Complex Biologics
- Biologics landscape trends and analysis from ADCs to Bispecifics.
- BSP’s expertise, services, and solutions to serve innovators in manufacturing complex biologics, with an overview on capabilities for cytotoxic and non-cytotoxic compounds.
12:45 pm Lunch
1:45 pm ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways
- Exploring how ZW1528 binds to both IL-4Ra and IL-33, and mediates potent blockade of IL-4, IL-13 and IL-33 enabling a broad and simultaneous inhibition of key inflammatory pathways
- Demonstrating translational relevance as ZW1528 inhibits Type 2 and non-Type 2 responses in vitro in primary immune cells of COPD patients, effectively modulating diverse immune pathways across patient subtypes
- Investigating how ZW1528 demonstrates IgG-like PK and biomarkers of target blockade in the NHP, supporting clinical viability through favourable pharmacokinetics and validated target engagement
2:15 pm Conditionally active 41BB Costimulatory CD19 x CD20 T Cell engager designed for deeper and durable responses and minimal cytokine release for Autoimmune Diseases
- Costimulation built in CD19 x CD20 T Cell Engager (TCE) to achieve CAR-T like potency, immune reset, and efficacy for Autoimmune diseases
- Conditional Activation of TCE only in the presence of antigen engagement overcomes cytokine release syndrome associated with conventional TCEs
- Shows increased potency and efficacy in the humanized SLE mouse model compared to benchmark TCE BlinatumomabTM and other CD19 and CD20 TCE’s in development for Autoimmune Diseases
2:45 pm Innovating Biologics Discovery using the NonaHCAbFx Platform
- The limitations of camelid nanobodies in bispecifics and the advantages of fully human HCAbs from Harbour Mice®.
- A novel function-based screening platform for identifying CD19-targeting HCAbs using a CAR-Jurkat reporter system.
- Discovery of fully human CD19 TCEs with superior cytotoxicity compared to reference molecules.
3:00 pm Afternoon Break & Poster Session
This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of bispecific experts eager to hear the latest innovations and positive movement, you will have the opportunity to display a poster presenting your own work. Additionally, you will have the chance to review others’ posters displaying cutting-edge work from drug discovery right through to exciting clinical trial updates.
3:50 pm IndEx-2: Assessing the impact of antigen density on the safety and efficacy of bispecifics
- A stable cell platform to precisely control target antigen expression over physiologically relevant expression levels, modelling healthy and disease states
- Orthogonal control of two target antigens in the same cell line to characterise single and dual-targeted therapeutics
- Integrated with real-time cytotoxicity, flow cytometry, and cytokine assays to select therapeutics with optimal characteristics by determining activation thresholds and informing therapeutic index, illustrated in a case study comparing a CD19-directed T cell engager CLN-978 vs. Blinatumomab
Strategic Target Selection for Optimizing Bispecific Design & Function
4:00 pm Panel Discussion: Strategic Target Selection for Optimizing Bispecific Design & Function
This panel will examine how aligning target biology, mechanism of action, and bispecific format is critical to therapeutic success. Experts will explore strategies for selecting and validating novel targets, addressing tumor heterogeneity, and optimizing design parameters to enhance efficacy while managing safety.
- How do you determine whether a target’s biology aligns with the intended mechanism of action of your bispecific construct?
- What are the key molecular design considerations? Looking at considerations, such as affinity, format, and valency for a selected target
- How can we better predict and manage unexpected biology that arises from targeting a molecule in a specific disease context?
- What approaches are most effective for validating novel targets, particularly in solid tumors with heterogeneous expression?
- How do different bispecific modalities (e.g., T-cell engagers, costimulatory bispecifics, ADCs) influence target selection strategy?
- How do you balance the therapeutic window by assessing target expression across tumor versus normal tissue to mitigate toxicity?
4:45 pm End of Conference Day One
4:55 pm Chair’s Closing Remarks
5:00 pm Drinks Reception & Poster Session
This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships with drinks and snacks provided. With an audience of bispecific experts eager to hear the latest innovations and positive movement, you will have the opportunity to display a poster presenting your own work. Additionally, you will have the chance to review others’ posters displaying cutting-edge work.